vimarsana.com

Latest Breaking News On - Pharmaceuticals price performance - Page 1 : vimarsana.com

CNS Pharmaceuticals Stock Set to Reverse Split on Wednesday, June 5th (NASDAQ:CNSP)

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Free Report)’s stock is scheduled to reverse split before the market opens on Wednesday, June 5th. The 1-50 reverse split was announced on Wednesday, June 5th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, June 5th. CNS Pharmaceuticals Price Performance NASDAQ:CNSP traded […]

Rafferty Asset Management LLC Acquires 91,317 Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

Rafferty Asset Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 427,930 shares of the biopharmaceutical company’s stock after purchasing an additional 91,317 shares during the period. Rafferty […]

Rafferty Asset Management LLC Acquires 91,317 Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

Rafferty Asset Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 427,930 shares of the biopharmaceutical company’s stock after purchasing an additional 91,317 shares during the period. Rafferty […]

CASI Pharmaceuticals, Inc (NASDAQ:CASI) Short Interest Up 14 7% in May

CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 53,100 shares, a growth of 14.7% from the April 30th total of 46,300 shares. Currently, 0.8% of the shares of the company are […]

ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. lowered their price target on shares of ORIC Pharmaceuticals from $19.00 […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.